In an apolipoprotein E-deficient atherosclerotic mice model, not a kidney disease model, Ervinna et al41 demonstrated that anagliptin exerted an antiatherosclerotic effect through inhibition of the inflammatory reaction of monocytes and inhibition of smooth muscle cell proliferation. Here, APOE is linked to kidney disorder.